# Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

> **NCT00835848** · PHASE4 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 100 (estimated)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT00835848
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-12
- **Final completion:** 2015-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835848, "Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00835848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*